These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 32294430)

  • 1. Cdk4 and Cdk6 Couple the Cell-Cycle Machinery to Cell Growth via mTORC1.
    Romero-Pozuelo J; Figlia G; Kaya O; Martin-Villalba A; Teleman AA
    Cell Rep; 2020 Apr; 31(2):107504. PubMed ID: 32294430
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
    Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
    Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Determinants of Cell Cycle Plasticity and Sensitivity to CDK4/6 Inhibition.
    Kumarasamy V; Vail P; Nambiar R; Witkiewicz AK; Knudsen ES
    Cancer Res; 2021 Mar; 81(5):1347-1360. PubMed ID: 33323381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature.
    Knudsen ES; Hutcheson J; Vail P; Witkiewicz AK
    Oncotarget; 2017 Jul; 8(27):43678-43691. PubMed ID: 28620137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.
    Spring LM; Zangardi ML; Moy B; Bardia A
    Oncologist; 2017 Sep; 22(9):1039-1048. PubMed ID: 28706010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
    Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
    Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences.
    Braal CL; Jongbloed EM; Wilting SM; Mathijssen RHJ; Koolen SLW; Jager A
    Drugs; 2021 Feb; 81(3):317-331. PubMed ID: 33369721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple effects of CDK4/6 inhibition in cancer: From cell cycle arrest to immunomodulation.
    Bonelli M; La Monica S; Fumarola C; Alfieri R
    Biochem Pharmacol; 2019 Dec; 170():113676. PubMed ID: 31647925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2.
    Pack LR; Daigh LH; Chung M; Meyer T
    Nat Commun; 2021 Jun; 12(1):3356. PubMed ID: 34099663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D-CDK4/6 functions in cancer.
    Gao X; Leone GW; Wang H
    Adv Cancer Res; 2020; 148():147-169. PubMed ID: 32723562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer.
    Robert M; Frenel JS; Bourbouloux E; Rigaud DB; Patsouris A; Augereau P; Gourmelon C; Campone M
    Drugs; 2018 Sep; 78(13):1353-1362. PubMed ID: 30143968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer.
    Michaloglou C; Crafter C; Siersbaek R; Delpuech O; Curwen JO; Carnevalli LS; Staniszewska AD; Polanska UM; Cheraghchi-Bashi A; Lawson M; Chernukhin I; McEwen R; Carroll JS; Cosulich SC
    Mol Cancer Ther; 2018 May; 17(5):908-920. PubMed ID: 29483206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    Wright GM; Gimbrone NT; Sarcar B; Percy TR; Gordián ER; Kinose F; Sumi NJ; Rix U; Cress WD
    PLoS One; 2021; 16(6):e0252927. PubMed ID: 34138895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib.
    Poratti M; Marzaro G
    Eur J Med Chem; 2019 Jun; 172():143-153. PubMed ID: 30978559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival.
    Martínez-Carreres L; Puyal J; Leal-Esteban LC; Orpinell M; Castillo-Armengol J; Giralt A; Dergai O; Moret C; Barquissau V; Nasrallah A; Pabois A; Zhang L; Romero P; Lopez-Mejia IC; Fajas L
    Cancer Res; 2019 Oct; 79(20):5245-5259. PubMed ID: 31395606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-cell growth and anti-cancer stem cell activity of the CDK4/6 inhibitor palbociclib in breast cancer cells.
    Kishino E; Ogata R; Saitoh W; Koike Y; Ohta Y; Kanomata N; Kurebayashi J
    Breast Cancer; 2020 May; 27(3):415-425. PubMed ID: 31823286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women.
    Cersosimo RJ
    Am J Health Syst Pharm; 2019 Aug; 76(16):1183-1202. PubMed ID: 31369120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma.
    Aliagas E; Alay A; Martínez-Iniesta M; Hernández-Madrigal M; Cordero D; Gausachs M; Pros E; Saigí M; Busacca S; Sharkley AJ; Dawson A; Palmero R; Ruffinelli JC; Padrones S; Aso S; Escobar I; Ramos R; Llatjós R; Vidal A; Dorca E; Varela M; Sánchez-Céspedes M; Fennell D; Muñoz-Pinedo C; Villanueva A; Solé X; Nadal E
    Br J Cancer; 2021 Nov; 125(10):1365-1376. PubMed ID: 34588615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.
    Kwapisz D
    Breast Cancer Res Treat; 2017 Nov; 166(1):41-54. PubMed ID: 28741274
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ribociclib, a selective cyclin D kinase 4/6 inhibitor, inhibits proliferation and induces apoptosis of human cervical cancer in vitro and in vivo.
    Xiong Y; Li T; Assani G; Ling H; Zhou Q; Zeng Y; Zhou F; Zhou Y
    Biomed Pharmacother; 2019 Apr; 112():108602. PubMed ID: 30784916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.